Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana M Zuckerman

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
American Journal of Public Health|December 8, 2016
A Major Shortcoming in the Public Health Legacy of the Obama AdministrationDiana M Zuckerman
American Journal of Public Health|May 5, 2021
Emergency Use Authorizations (EUAs) Versus FDA Approval: Implications for COVID-19 and Public HealthDiana M Zuckerman
American Journal of Public Health|October 12, 2017
Can the FDA Help Reduce Drug Prices or the Cost of Medical Care?Diana M Zuckerman
Reproductive Health Matters|June 15, 2010
Reasonably safe? Breast implants and informed consentDiana M Zuckerman
JAMA Internal Medicine|May 5, 2015
Sufficiency of Information in 510(k) Summaries-ReplyDiana M Zuckerman, Paul Brown
Cancer Epidemiology|July 23, 2014
Lack of diversity in cancer drug clinical trials may exacerbate racial disparities in mortality ratesLaurén A Doamekpor, Diana M Zuckerman
Environmental Science & Technology|July 11, 2014
Comment on "Silicone wristbands as personal passive samplers"Anna E Mazzucco, Diana M Zuckerman
Annals of Internal Medicine|April 7, 2017
Electronic Health RecordsJay G Ronquillo, Diana M Zuckerman
The Milbank Quarterly|September 13, 2017
Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital HealthJay G Ronquillo, Diana M Zuckerman
The Milbank Quarterly|March 7, 2014
Regulatory reticence and medical devicesDaniel M Fox, Diana M Zuckerman
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
American Journal of Public Health|December 8, 2016
A Major Shortcoming in the Public Health Legacy of the Obama AdministrationDiana M Zuckerman
American Journal of Public Health|May 5, 2021
Emergency Use Authorizations (EUAs) Versus FDA Approval: Implications for COVID-19 and Public HealthDiana M Zuckerman
American Journal of Public Health|October 12, 2017
Can the FDA Help Reduce Drug Prices or the Cost of Medical Care?Diana M Zuckerman
Reproductive Health Matters|June 15, 2010
Reasonably safe? Breast implants and informed consentDiana M Zuckerman
JAMA Internal Medicine|May 5, 2015
Sufficiency of Information in 510(k) Summaries-ReplyDiana M Zuckerman, Paul Brown
Cancer Epidemiology|July 23, 2014
Lack of diversity in cancer drug clinical trials may exacerbate racial disparities in mortality ratesLaurén A Doamekpor, Diana M Zuckerman
Environmental Science & Technology|July 11, 2014
Comment on "Silicone wristbands as personal passive samplers"Anna E Mazzucco, Diana M Zuckerman
Annals of Internal Medicine|April 7, 2017
Electronic Health RecordsJay G Ronquillo, Diana M Zuckerman
The Milbank Quarterly|September 13, 2017
Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital HealthJay G Ronquillo, Diana M Zuckerman
The Milbank Quarterly|March 7, 2014
Regulatory reticence and medical devicesDaniel M Fox, Diana M Zuckerman
Pageof 2